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Cognitive and Graded Activity Training Can Alleviate
Persistent Fatigue After Stroke
A Randomized, Controlled Trial
Aglaia M.E.E. Zedlitz, MSc; Toni C.M. Rietveld, PhD; Alexander C. Geurts, MD, PhD; Luciano Fasotti, PhD
Background and Purpose—Fatigue is a common, persistent consequence of stroke, and no evidence-based treatments are
currently available to alleviate fatigue. A new treatment combining cognitive therapy (CO) with graded activity training
(GRAT), called COGRAT, was developed to alleviate fatigue and fatigue-related symptoms. This study compared the
effectiveness of the COGRAT intervention with a CO-only intervention after a 3-month qualification period without
intervention.
Methods—This randomized, controlled, assessor-blind clinical trial was conducted in 8 rehabilitation centers. Eighty-three
stroke patients (4 months after stroke) were randomly assigned to 12 weeks of CO or COGRAT after qualification.
Seventy-three patients completed treatment and 68 were available at follow-up. Primary outcomes (Checklist Individual
Strength–subscale Fatigue (CIS-f); self-observation list–fatigue (SOL-f)) and secondary outcomes (Hospital Anxiety
and Depression Scale, Stroke-Adapted Sickness Impact Profile, SOL-pain, SOL-sleep-D, 6-minute walk test) were
collected at baseline (before and after qualification period) and after treatment (immediate and 6-month follow-up).
Results—The qualification period showed stable outcome measures. Both treatments showed significant beneficial effects
on fatigue (CIS-f: p20.48, P0.001) and other outcomes (except pain and anxiety) with intention-to-treat analyses.
Gains for the COGRAT group exceeded those in the CO group on number of individuals showing clinical improvement
on the CIS-f (8 points: 58% versus 24%) and on physical endurance (p20.20, P0.001).
Conclusions—A 12-week cognitive therapy program can alleviate persistent fatigue after stroke. The best results are
obtained when cognitive therapy is augmented with graded activity training.
Clinical Trial Registration—URL: http://www.trialregister.nl. Unique identifier: NTR2704.
(Stroke. 2012;43:1046-1051.)
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Fatigue is a common and often persisting consequence ofstroke that negatively affects rehabilitation outcome, func-
tional independency in daily life activities, quality of life, and
mortality.1,2 Although the definition of poststroke fatigue (PSF)
is still subject of debate,1,2 it is generally agreed that it is “a
subjective experience of extreme and persistent tiredness, weak-
ness or exhaustion after stroke, which can present itself mentally,
physically or both and is unrelated to previous exertion lev-
els.”1–4 Prevalence rates are as high as 38–73% without spon-
taneous amelioration in the chronic phase.1 Moreover, research
on its natural history shows that PSF often does not diminish
even years after stroke.4–7 The etiology of PSF appears to be
multifactorial. On the one hand, direct relationships have been
described between the type and extent of the brain lesion, with
infratentorial lesions, infarction of the basal ganglia, and recur-
rent stroke yielding a greater risk of fatigue.1,4,8,9 On the other
hand, depression, anxiety, reduced functional health status, sleep
disturbances, pain, and poor physical fitness have all been
associated with PSF.1 Overall, the exact mechanisms of origin
and persistence of PSF are still elusive,1 and no effective
pharmacological or nonpharmacological treatment for PSF is yet
available.2
Evidence from other patient populations with chronic
fatigue suggests that tailored cognitive behavioral therapy,
exercise therapy,10,11 and teaching energy conservation strat-
egies12 are effective means to alleviate chronic fatigue and
related psychological and physical symptoms. Against this
background, we developed a 12-week group cognitive treat-
ment (CO) tailored to the stroke population, including ele-
ments of cognitive behavioral therapy (CBT) and teaching
compensation strategies aimed at pacing and relaxation.13 A
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Graded Activity Training (GRAT) was offered alongside the
cognitive treatment. GRAT consisted of walking on a tread-
mill, strength training, and physical fitness home work
assignments. A full description of these interventions has
been published previously.13
The aim of this study was to compare the effectiveness of
a combined intervention (COGRAT) with that of CO alone
on fatigue and associated psychological and physical vari-
ables. Because the long-term beneficial effects of physical
fitness training after stroke are still subject to debate and
because functional benefits of physical training tend to taper
off at a later stage,14 we did not include a separate GRAT
group. We hypothesized that both CO and COGRAT would
alleviate fatigue, but COGRAT would be more effective than
CO alone, especially with regard to physical endurance.
Methods
Study Design
A multicenter, randomized, controlled study preceded by a qualifi-
cation period was designed using block randomization per treatment
center. Outcome measures were administered by blinded assessors
and were gathered via self-report questionnaires. Patients did not
receive feedback on any of the assessments during the trial.
Eligible patients were first assessed on the primary and secondary
outcome measures (T0) and then entered a waiting list period of 3
months, during which no rehabilitation took place. The benefits of this
so-called “qualification period” are that previous therapeutic effects are
washed out, that poor compliers can be identified before random
assignment, and that a stable baseline of the outcome measures can
potentially be established.15 Immediately after the qualification period,
the outcome measures were administered again (T1).
Thereafter, when 8 patients were available at a center, random
assignment of individual patients to an intervention group (CO or
COGRAT) took place by means of 8 sealed envelopes. If only 4
patients were available at a center, all patients were assigned to 1
intervention group by means of a sealed envelope. Directly after
treatment another assessment took place (T2); a follow-up assess-
ment was performed after 6 months (T3).
The study was approved by the regional Medical-Ethical Committee
for Research Involving Human Subjects and the local Medical-Ethical
Committees of the 8 participating Dutch rehabilitation centers. The
study was conducted according to the Declaration of Helsinki16 stan-
dards. All patients provided written informed consent.
Patients
Between April 2008 and February 2010, community-dwelling pa-
tients who had had a stroke were approached through their treating
physicians and psychologists, through newspaper articles, or based
on participation in previous studies. Patients were eligible if they (1)
had sustained a stroke 4 months before recruitment, (2) reported
severe fatigue (Checklist Individual Strength–subscale Fatigue score
40),7,17 (3) were between ages 18–70 years, and (4) were able to
walk independently. Patients were excluded if they had severe
cognitive deficits (Behavioral Inattention Test 129, Rivermead
Behavioral Memory Test-screening score 8, Behavioral Assess-
ment of the Dysexecutive Syndrome less than borderline, Token
Task 12)18 or severe comorbidity, such as cardiac disease, pulmo-
nary disease, or depression (Hospital Anxiety and Depression Scale–
depression subscale score 10,19 or based on a clinical DSM-IV
interview20 if the Hospital Anxiety and Depression Scale (HADS)
depression subscore was 8, 9, or 10). Demographic and neurological
data (age, sex, living situation, education level, previous rehabilita-
tion treatments, stroke type and hemisphere, time after onset of
stroke, single versus recurrent stroke, Motricity Index21) were
obtained from the medical files.
Interventions
Based on the results of a pilot study to test the effects of cognitive
treatment (emphasizing pacing and relaxation) on fatigue and psy-
chological distress in patients with stroke, the size of the CO groups
was set to a maximum of 4 patients.13 In addition, a GRAT protocol
was designed including walking on a treadmill, strength training, and
home work assignments. Maximum heart rate and strength were
slowly increased from 40% at the beginning of the training to a
maximum of 70% at the end of the 12-week program, based on
recommendations by the American Heart Association.13,22 GRAT
was given in groups of maximally 4 patients as well. The CO group
received weekly 2-hour sessions of cognitive therapy for 12 weeks,
In addition to group CO, the COGRAT group received 24, 2-hour
sessions of GRAT twice a week for 12 weeks. During the study
interventions, no other treatments were given.
The neuropsychologists giving CO and the physiotherapists giving
GRAT were all experienced in the rehabilitation of patients with
stroke and worked within an academic setting. The neuropsycholo-
gists were also proficient in CBT. All therapists were trained and
supervised by the principal investigator (A.Z.). All participants
received daily homework assignments to enhance the therapeutic
objectives. After each session, therapists rated patient attendance and
patient adherence to treatment and homework on a 5-point Likert
scale. Therapists also rated the percentage of the protocol that they
had followed after each session.
Primary Outcomes
The Checklist Individual Strength–subscale Fatigue (CIS-f)17 and a
fatigue self-observation list (SOL-f)23 were used to obtain informa-
tion on patient’s fatigue. Both tools are well validated and are widely
used in the Benelux countries.9,23–25 The CIS-f contains 8 questions
on fatigue severity regarding the 2 weeks preceding the assessment.
The CIS-f has good reliability, is sensitive to change,3,17 and has
been validated for the stroke population.7,9 Questions are answered
on a 7-point Likert scale (1–7; summed range, 8–56; higher scores
represent greater fatigue). Patients with a score 40 were regarded
as severely fatigued.7,23 With the validated SOL-f, patients recorded
their fatigue severity on a 5-point scale (0–4) 4 times a day
(morning, afternoon, evening, and bed time) for 7 days. The daily
fatigue score was the sum of these 4 scores (range, 0–16). The
average daily fatigue score was calculated.23–25
Secondary Outcomes
Depression and anxiety were assessed with the HADS.19 The HADS
has been validated in patients with stroke, and it consists of 14 items
scored on a 4-point Likert scale (0–3): 7 items on the depression
subscale (HADS-D) and 7 items on the anxiety subscale (HADS-
A).26 Subscale sum scores are categorized as normal (0–7), mild
(8–10), moderate (11–14), or severe (15–21).27
Functional health status was assessed with the well-validated
Stroke-Adapted Sickness Impact Profile 30 (SA-SIP 30).28 This tool
has 30 items, and scores are calculated as a percentage of maximum
dysfunction, ranging from 0–100%. A higher score indicates poorer
functioning. In a well-validated self-observation list (SOL), patients
recorded the amount of pain they experienced 4 times a day on a
5-point scale (0–4). For each patient, a mean pain score per day is
available (SOL-pain, range 0–16).24,25 An SOL was also used to
record the quality of sleep. Patients indicated whether they had slept
well or recorded which of 3 sleep disturbances had occurred that
night (difficulty falling asleep, restless sleep, early awakening). The
amount of sleep disturbances was totaled for each day (0–3). Scores
were then expressed as the average amount of sleep disturbances per
night (SOL-Sleep D; range, 0–3).24,25
The 6-minute walk test (6MWT) is a validated tool to assess
physical endurance.29 The total walking distance in meters during 6
minutes was recorded.
Furthermore, after treatment (T2), patients were given a Visual
Analog Scale (VAS: range, 0–10) to report patient satisfaction
asking the question: “If I had to rate my satisfaction on treatment, I
would rate it ….”
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Clinically Important Change
Clinically relevant improvement on the CIS-f was determined at
follow-up (T3). At a group level, this was defined as a score 35.
This score is situated within 2 standard deviations of CIS-f scores in
healthy control subjects.23,25,30 At an individual level, a clinically
important reduction of fatigue was set at a reliable change index
(RCI)1.96. This corresponds with a CIS-f score decrease of at least
8 points. This decrement has previously been reported as a clinically
important improvement in individuals with fatigue.23,30
Statistical Analysis
It was calculated that a sample size of 48 patients per treatment group
would be needed to detect a clinically relevant difference of 8 CIS-f
points with a  value of 0.10 and an  level of 0.05.23,30 Data
analyses were performed using SPSS (version 18.0). Holm correc-
tion was used to control for multiple outcomes.31
Descriptive statistics were used to summarize demographic,
stroke, and baseline clinical characteristics. We then established
whether changes on any of the outcome measures had occurred
during the qualification period (T0 versus T1) using paired t tests.
All further analyses were performed on an intention-to-treat basis.
Any missing values after treatment were imputed by carrying the last
observation forward, adhering a conservative assumption with re-
spect to treatment effects.
As a first step, analysis of covariance (ANCOVA) with the baseline
scores as covariate was applied to the data. The interaction between
group and the covariate was significant for all outcome variables, which
indicated nonparallel regression. For this reason, multiple analysis of
variance (MANOVA) was done to establish treatment effects using time
(T1, T2, T3) as a within-subjects factor and group (CO, COGRAT) as
a between-subjects factor. Effect sizes were expressed in partial eta
squared values (p2), which range from 0–1.
To establish the percentage of patients with clinically significant
improvement in fatigue, CIS-f scores were dichotomized into clini-
cally significant (RCI 1.96) and clinically nonsignificant (RCI
1.96).30 We used the 2 test and associated contingency coeffi-
cients to examine between-group differences.
To test whether any of the baseline characteristics was associated
with study withdrawal or dropout, 2 tests were used for categorical
variables and unpaired t tests for interval data.
To investigate whether stroke characteristics affected treatment
outcome, post hoc analyses were performed for stroke type (ische-
mic, hemorrhage, subarachnoid hemorrhage [SAH], and mixed),
single versus recurrent stroke, and post–onset time regarding all
outcome measures at baseline and follow-up using analyses of
variance (ANOVA) or t tests.
Results
Patients
Patient flow (n231) throughout the study is illustrated in the
consort diagram in Figure 1. The main reasons for nonpar-
ticipation were a CIS-f score 40 (n47) and symptoms of
depression (n21). Due to insufficient numbers of eligible
patients at the different centers, individual random assign-
ment of 6 and 7 patients took place in several instances. As a
result, some treatment groups contained 3 patients. Of the 83
patients randomly allocated to a treatment group, 73 com-
pleted the treatment and were assessed at T2 (39 CO and 34
COGRAT). Of the 10 patients who discontinued treatment, 6
were assessed at T2. At follow-up (T3), 68 patients (82%)
were still available for assessment.
Mean post–onset time of stroke in participants was 3.9
years (SD, 3.9). For 5 patients, post–onset time exceeded 10
years. Sixty-three patients had been given prior rehabilitation
(75.9%). More than half of all participants had received
physiotherapy (61.4%) and/or occupational therapy (50.6%).
Demographic and clinical characteristics of both treatment
groups are listed in Table 1. None of these characteristics was
associated with study withdrawal (n5; 6%) or discontinua-
tion of treatment (n10; 12%; all P0.05).
Primary and Secondary Outcomes
Before the start of the interventions, after the 3 months
qualification period, no significant change was found for any
of the primary or secondary outcome measures. The values of
the primary and secondary outcomes after the qualification
period, at T1, T2, and T3, are shown in Table 2. For the
primary outcomes, after the treatment, main effects of time
were found (CIS-f P0.001; SOL-f P0.007). Effect sizes
were substantial for CIS-f (p20.48) and less for SOL-f
(p20.12). No interaction effects of time with group were
found for either fatigue measures. Figure 2 illustrates that
time effects mainly occurred between T1 and T2 and re-
mained stable at T3.
Figure 1. Consort diagram. CIS-f indicates
Checklist Individual Strength–subscale
Fatigue; TIA, transient ischemic attack.
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Small but significant main effects of time were found for
all secondary outcomes, except pain and anxiety. These
effects also occurred between T1 and T2 and were stable at
T3. Of all secondary outcomes, the 6MWT showed the
greatest time effect, and there was a significant interaction
effect with group (P0.001, p20.20). Figure 3 indicates
that after treatment and at follow-up, physical endurance had
improved more in the COGRAT group than in the CO group.
Clinically Important Change
At follow-up, only the mean CIS-f score of the COGRAT
group had improved to 35. In contrast, the mean CIS-f
score of the CO group was still (albeit marginally) higher
than this cutoff score (Table 2). At an individual level, more
patients in the COGRAT group showed a clinically relevant
improvement on the CIS-f than those receiving CO only
(P0.002) (Table 3).
Control for Confounding Variables
Mean patient satisfaction was high (VAS, 7.8) and did not
differ between the treatment groups. Therapist adherence to
the treatment protocol was98% in both groups. Overall, the
patients showed good treatment compliance. There were no
statistical differences between groups for the number of CO
sessions (median, 11 of 12) or completed homework assign-
ments (nearly always). The median number of GRAT ses-
sions followed in the COGRAT group was 23 of 24.
Post hoc analyses revealed no effects of stroke character-
istics (stroke type, single versus recurrent stroke, post–onset
time) on any of the outcome measures (all P0.05). Separate
trend analyses of the outcome measures leaving out patients
with SAH yielded the same statistically significant main and
interaction effects, except for a nonsignificant effect of time
on SOL-f (F(70)3.98, P0.023) (nonsignificant after Holm
correction for multiple outcomes).
Discussion
The results of this multicenter, randomized, controlled trial
indicate that a cognitive therapy combined with graded
activity training during a 12-week period reduces persistent
PSF. Furthermore, beneficial effects remain stable at
follow-up and are not only found on 2 different measures of
fatigue but also on functional health status, symptoms of
depression, sleep, and physical endurance. To our knowledge,
this is the first study reporting significant reduction of PSF
and related symptoms after a comprehensive treatment spe-
cifically tailored to the needs of this population.
Our results largely support the hypothesis that the addition of
GRAT to cognitive therapy leads to a greater reduction of
fatigue than when administering CO alone. Although at a group
level both treatments resulted in almost similar benefits on the
CIS-f, 58% of the COGRAT patients compared with 24% of the
CO patients showed clinically relevant improvement at follow-
up. In addition, as expected, physical endurance improved more
after COGRAT than after CO alone. Directly after treatment, the
increment in distance walked after COGRAT had almost
reached the minimally important change of 70 m.29 At follow-
up, however, this improvement had decreased to approximately
40 m. This pattern of results suggests that (besides the physical
benefits) improving physical endurance may help reduce PSF
complaints. However, such an improvement is not a prerequisite
for lasting beneficial effects of cognitive therapy on PSF.
The major strengths of this study are its multicenter design,
the 3-month qualification period without any treatment,
and the high level of treatment compliance and patient
adherence. Although no independent rating of therapist ad-
herence was performed, no conflicts of interest were present
and all therapists had prior experience with scientific proto-
cols. In addition, patients were generally satisfied with both
treatments, and the number of dropouts remained within
acceptable limits.32 Moreover, 4 of the 10 patients who did
not complete their treatment withdrew for reasons unrelated
to the intervention (Figure 1), suggesting that both treatments
were well tolerated.
This study has, however, several limitations. The specific
improvement in PSF due to COGRAT or CO cannot be
teased out due to the absence of a sham control treatment. In
Table 1. Demographic and Clinical Characteristics of
Patients (n83)
CO
Mean (SD)
COGRAT
Mean (SD)
n 45 38
Age, y 54.8 (9.1) 55.6 (8.8)
Men, % 48.9% 55.3%
Living alone, % 24.4% 10.8%
Education, median: 1lowest, 7highest 5 (1.1) 5 (1.3)
MI 90.2 (15.0) 90.1 (12.1)
Stroke
Time since last stroke, y 4.4 (4.2) 3.3 (3.9)
1 y after stroke, % 8.9% 13.2%
1–2 y after stroke, % 26.7% 34.2%
2–5 y after stroke, % 40.0% 34.2%
5–10 y after stroke, % 15.6% 15.8%
10 y after stroke, % 8.9% 2.6%
Range 0.8–22.2 0.4–23.0
Single 75.6% 73.7%
Recurrent 24.4% 26.3%
Stroke type
Ischemic LH/RH/bilateral 7/23/1 10/18/2
Hemorrhage LH/RH/bilateral 1/1/1 3/0/0
Subarachnoid hemorrhage 7 2
Other (infarct cerebellum and mixed) 4 3
Prior rehabilitation 75.6% 76.3%
Mean No. of prior treatments (SD) 2.6 (1.8) 2.1 (1.8)
Physiotherapy, % 60.0% 63.2%
Occupational therapy, % 51.1% 50.0%
Speech therapy, % 26.7% 23.7%
Cognitive therapy, % 31.1% 31.6%
Psychological treatment, % 57.8% 36.8%
Specialist counseling, % 2.2% 0
CO indicates cognitive treatment; COGRAT, cognitive and graded activity
training; MI, Motricity Index; LH, left hemisphere; RH, right hemisphere.
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addition, post–onset times in our study varied considerably,
with 5 patients having had a stroke 10 years before
enrollment. Because we did not assess the full medical history
of comorbidities, we cannot attribute the presence of persis-
tent fatigue solely to stroke in each patient. Yet, patients with
a depression or severe cardiac or pulmonary disease were
excluded. In addition, PSF has repeatedly been found to be a
chronic condition, with prevalence rates remaining relatively
stable even years after stroke.4–7 Because no significant
changes occurred in any of the outcome measures during the
qualification period, the beneficial effects observed after
treatment are probably attributable to the intervention.
Two sources of heterogeneity in our study sample may be
considered limitations: stroke etiology and previous treat-
ment. Because we included not only first-time infarctions but
also hemorrhages, SAH, and recurrent stroke, we cannot
relate the observed treatment effects to any type of brain
lesion. However, in our data, no influence of stroke type on
treatment effects was found, and, in the literature, prevalence
rates of fatigue do not differ markedly between stroke
types.1,33 Although more patients with SAH were allocated to
the CO than to the COGRAT group (7 versus 2) and
prognosis and complications after SAH differ from ischemic
infarctions, the patients with SAH in this study did not differ
from the other patients on any of the demographic character-
istics or outcome measures at any point in time. The fact that
the effect of time ceased to be significant for SOL-f when
excluding patients with SAH is probably due to a loss of
power, since all other effects remained unaltered. The etio-
logic heterogeneity can also be considered as a strength for it
indicates the effectiveness of COGRAT in a large variety of
patients, irrespective of etiology. The strict eligibility criteria
with regard to ambulation and cognition, however, limit the
generalizability of the results to other patients.
Patients also differed with regard to the amount and type of
prior rehabilitation they had received. We were unable to
Figure 2. Checklist Individual Strength–subscale Fatigue (CIS-f)
scores at the 4 time points for the cognitive therapy (CO) and
CO with graded activity training (COGRAT) groups (n83).
Figure 3. Six-minute walk test: Distance walked in meters at the
4 time points for the cognitive therapy (CO) and CO with graded
activity training (COGRAT) groups (data of 1 patient are missing
on all 4 occasions; n82).
Table 2. Outcome Measurements (n83)
Outcome Variables
Mean (SD) Analyses
CO COGRAT Time* Group* Interaction*
T1 T2 T3 T1 T2 T3 F P p
2 F P F P
CIS-f 42.1 (8.0) 34.8 (11.1) 35.5 (11.5) 44.6 (7.0) 35.6 (9.5) 33.5 (10.5) 37.74 0.001† .48 0.06 0.1 2.16 0.121
SOL-f 5.8 (2.3) 5.3 (2.6) 5.5 (2.7) 6.0 (2.7) 5.0 (2.3) 5.0 (2.6) 5.24 0.007† .12 1.39 0.1 1.39 0.256
HADS-D 6.6 (3.1) 5.6 (3.3) 5.7 (3.3) 7.7 (2.7) 6.4 (2.6) 6.1 (3.4) 6.54 0.002† .14 2.25 0.1 0.12 0.884
HADS-A 6.9 (4.1) 6.0 (3.8) 6.1 (4.0) 6.6 (3.9) 5.6 (2.9) 5.8 (3.6) 3.50 0.035 .08 0.19 0.1 0.04 0.963
SA-SIP 18.2 (10.6) 18.1 (11.5) 16.4 (11.0) 21.1 (13.1) 15.4 (12.1) 15.7 (13.9) 6.69 0.002† .14 0.00 0.1 3.25 0.044
SOL-sleep D 0.71 (0.64) 0.58 (0.56) 0.57 (0.56) 0.71 (0.49) 0.60 (0.58) 0.49 (0.51) 5.25 0.007† .12 0.03 0.1 0.67 0.516
SOL-pain 2.3 (2.7) 2.3 (2.7) 2.1 (2.6) 1.9 (2.4) 1.8 (2.2) 1.9 (2.7) 0.27 0.765 .01 0.41 0.1 0.17 0.841
6MWT 438 (123) 444 (112) 441 (123) 437 (107) 504 (94) 481 (92) 14.43 0.001† .27 1.98 0.1 9.72 0.001†
CO indicates cognitive treatment; COGRAT, cognitive and graded activity training; CIS-f, Checklist Individual Strength-Fatigue Severity Scale; SOL, Self-Observation
List (-f: fatigue severity scale; -sleep D, sleep disturbances); HADS, Hospital Anxiety and Depression Scale (D, depression subscale; A, anxiety subscale); SA-SIP, Stroke
Adapted Sickness Impact Profile 36; 6MWT, Six-minute walk test.
*df values are omitted to improve legibility.
†Significant with Holm correction for multiple outcomes: P0.008 for time and P0.043 for interaction effect.
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determine post hoc the nature and amount of fatigue-relieving
strategies offered in these treatments. Nevertheless, all pa-
tients still had severe fatigue complaints at study entry, and
no significant changes were detected during the 3-month
qualification period.
Future studies should also incorporate (severely) fatigued
patients with more pronounced cognitive and/or physical
sequelae of stroke. To this aim, the cognitive treatment might
be modified by using a more directive approach and by
involving the primary caregivers.
In conclusion, this is the first controlled study showing that
cognitive therapy can alleviate persistent fatigue complaints
after stroke. However, the best results are obtained when
cognitive therapy is augmented with graded activity training.
Because fatigue is known to have a negative impact on
functional independence and quality of life after stroke,
lasting treatment effects on persistent PSF potentially have a
major impact on rehabilitation outcome.
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Table 3. Clinically Relevant Improvement (n83)
CO, n (%) COGRAT, n (%)
Improvement 11 (24.4%) 22 (57.9%)
No improvement 34 (75.6%) 16 (42.1%)
CO indicates cognitive treatment; COGRAT, cognitive and graded activity
training.
Clinically relevant improvement (see text for definition).
Likelihood ratio: 29.63, P0.002; Contingency coefficient0.322.
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